We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:

Search Results

Showing 1-20 of 2,064 results
  1. Long-term topical corticosteroid treatment for atopic dermatitis: an in-depth analysis of safety, efficacy, withdrawal, and patient experiences

    Atopic dermatitis, often referred to as eczema, is classified as a chronic inflammatory skin disorder with increasing prevalence. Topical...

    Alyssa Ingurgio in Drugs & Therapy Perspectives
    Article 09 July 2024
  2. Pharmacologic hyperreactivity of kappa opioid receptors in periaqueductal gray matter during alcohol withdrawal syndrome in rats

    Background

    Periaqueductal gray matter (PAG) is a brain region rich in kappa-opioid receptors (KOR). KOR in PAG mediates behavioral responses related...

    Priscila Vázquez-León, Abraham Miranda-Páez, ... Bruno A. Marichal-Cancino in Pharmacological Reports
    Article 02 September 2023
  3. Pharmacological management of psychoactive substance withdrawal syndrome

    Rationale

    Medications are available to manage alcohol and drug withdrawal, but they are underutilized. Only a handful, such as methadone,...

    Dimy Fluyau, Sarah Clare Cook, ... Neelambika Revadigar in Drugs & Therapy Perspectives
    Article 19 October 2021
  4. Molecular pattern of a decrease in the rewarding effect of cocaine after an escalating-dose drug regimen

    Background

    Long-term cocaine exposure leads to dysregulation of the reward system and initiates processes that ultimately weaken its rewarding...

    Karolina Kołosowska, Małgorzata Lehner, ... Aleksandra Wisłowska-Stanek in Pharmacological Reports
    Article Open access 31 December 2022
  5. Long-term use of systemic azole antifungals can result in hepatotoxicity and other serious adverse effects

    Long-term use of systemic azole antifungals (i.e. fluconazole, isavuconazole, itraconazole, ketoconazole, posaconazole and voriconazole) can result...

    Article 16 December 2019
  6. Opioid misuse in older patients requires careful consideration of many factors

    There is insufficient clinical data on how to optimally treat and manage opioid misuse in older patients. Opioid use affects older adults differently...

    Article 09 November 2022
  7. Educate patients with medication overuse headache, and intervene, when necessary

    Medication overuse headache (MOH) most commonly affects people with migraine, particularly in patients who overuse medications intended for...

    Caroline Fenton, Arnold Lee in Drugs & Therapy Perspectives
    Article 10 November 2021
  8. Pharmacovigilance to Inform Drug Safety: Challenges and Opportunities

    Pharmacovigilance is vital to ensure the short-term and long-term safety of medications and other medicinal substances. Both active and passive...
    Reference work entry 2023
  9. Sparsentan in immunoglobulin A nephropathy: a profile of its use

    Sparsentan (FILSPARI ® ), an oral, dual endothelin and angiotensin receptor antagonist, is an emerging new treatment option for patients with...

    Young-A Heo, Connie Kang in Drugs & Therapy Perspectives
    Article 29 March 2024
  10. Amantadine extended release capsules (GOCOVRI®) in Parkinson’s disease: a profile of its use in the USA

    Amantadine extended release (ER) [GOCOVRI ® ], an NMDA receptor antagonist, is an important treatment option in the management of levodopa-induced...

    Zaina T. Al-Salama in Drugs & Therapy Perspectives
    Article Open access 01 May 2022
  11. Eczematous drug eruptions mostly manageable with emollients and corticosteroids

    Eczematous drug eruptions (EDEs) constitute up to 10% of cutaneous drug reactions, with biologics and some newer cancer treatments and antivirals...

    Caroline Fenton, Connie Kang in Drugs & Therapy Perspectives
    Article 06 December 2021
  12. Further proof on the role of accumbal nNOS in cocaine-seeking behavior in rats

    Background

    Cocaine use disorder (CUD) remains a severe health problem with no effective pharmacological therapy. One of the potential pharmacological...

    Małgorzata Frankowska, Irena Smaga, ... Małgorzata Filip in Pharmacological Reports
    Article 14 March 2024
  13. Effects of Chrysin on mRNA Expression of 5-HT1A and 5-HT2A Receptors in the Raphe Nuclei and Hippocampus

    5-Hydroxytryptamine-1A and 5-hydroxytryptamine-2A receptors have been widely related to the mechanism of action of antidepressant drugs. However, the...

    León Jesús German-Ponciano, Gilberto Uriel Rosas-Sánchez, ... Juan Francisco Rodríguez-Landa in Revista Brasileira de Farmacognosia
    Article 01 June 2021
  14. Gout plus cardiovascular disease is painful, but treatable

    Gout often coexists with and worsens cardiovascular disease (CVD) or CVD risk factors. Effective gout management reduces CVD deterioration, which...

    Caroline Fenton, Arnold Lee in Drugs & Therapy Perspectives
    Article 18 August 2021
  15. Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies

    The evaluation of dolutegravir based on available preclinical and clinical studies reveals a risk of central nervous system (CNS) disorders...

    Alicja Jakimiuk, Agnieszka Piechal, ... Dagmara Mirowska-Guzel in Pharmacological Reports
    Article Open access 21 August 2023
  16. Characteristics of Anticancer Drugs Approved Under the Accelerated Approval Program in the US: Success or Failure in Converting to Regular Approval

    Background

    Accelerated approval (AA) program expedites access to promising drugs for life-threatening conditions, particularly in oncology. However,...

    Yoshihiro Oda, Mamoru Narukawa in Therapeutic Innovation & Regulatory Science
    Article 04 January 2024
  17. MDPV (3,4-methylenedioxypyrovalerone) administered to mice during development of the central nervous system produces persistent learning and memory impairments

    Background

    Synthetic cathinones (SC) constitute the second most frequently abused class of new psychoactive substances. They serve as an alternative...

    Katarzyna Kuczyńska, Katarzyna Bartkowska, ... Jakub Wojcieszak in Pharmacological Reports
    Article Open access 09 May 2024
  18. The effect of phencyclidine-mediated blockade of NMDA receptors in the early postnatal period on glutathione and sulfur amino acid levels in the rat brain as a potential causative factor of schizophrenia-like behavior in adulthood

    Background

    Phencyclidine, an NMDA receptor antagonist, is frequently used to model behavioral and neurochemical changes correlated with schizophrenia...

    Elżbieta Lorenc-Koci, Magdalena Górny, ... Zofia Rogóż in Pharmacological Reports
    Article Open access 21 June 2024
  19. Chronic cerebral hypoperfusion-induced memory impairment and hippocampal long-term potentiation deficits are improved by cholinergic stimulation in rats

    Background

    Chronic cerebral hypoperfusion (CCH) can induce the accumulation of reactive oxygen species, which leads to oxidative damage, neuronal...

    Thenmoly Damodaran, Christian P. Müller, Zurina Hassan in Pharmacological Reports
    Article 30 January 2019
  20. Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA

    Buprenorphine extended-release (ER) injection for subcutaneous use (Brixadi ® ; CAM2038; hereafter referred to as buprenorphine ER) is a useful...

    Hannah A. Blair in Drugs & Therapy Perspectives
    Article Open access 01 February 2024
Did you find what you were looking for? Share feedback.